INTRODUCTION
The development of new therapeutic agents from synthesis through market entry is a costly and time-consuming process (Adams and Brantner, 2006; Taylor, 2015) . Novel preclinical assays that help predict drug behavior in humans prior to clinical analysis offer promising approaches to reduce the cost and time spent on this process (Brodniewicz and Grynkiewicz, 2010) .
In the last decade, several in vitro and in vivo model systems have been employed in preclinical tests. Human cell culture assays have often been used as screening tools in the initial stages of preclinical research, especially by providing mechanistic approaches to chemical-biological interactions (Allen et al., 2005) . Different cell models, including fibroblasts (Voytik-Harbin et al., 1998; Lee et al., 2000) , lymphocytes (Ahmed et al., 1994; de Fries and Mitsuhashi, 1995) , hepatocytes (Spryszynska et al., 2015; Wang et al., 2015) , and cardiomyoblasts (Sardao et al., 2009; Moreira et al., 2014) , as well as different cancer cell lines (Serafim et al., 2008 (Serafim et al., , 2011 , have been used to predict toxicological and pharmacological effects of compounds of interest. Human fibroblast cultures have been widely used in preclinical tests due to the ease of harvesting them from a large number of patients and the simplicity of the cell-culture procedures. The abundant availability of fibroblast lines with known genetic defects in worldwide cell banks also allows easy application of these cells to study effects and mechanisms of specific conditions, e.g., neurological diseases (Connolly, 1998) . In fact, it has been proposed that skin fibroblasts are a good predictive model to investigate neurological disorders, principally because they exhibit the same phenotypic alterations found in the central nervous systems of patients (Fairbanks et al., 2002; Garrido-Maraver et al., 2012; Ambrosi et al., 2014; Mocali et al., 2014; Nguyen, 2014; Yang et al., 2015) . Human fibroblasts have also been used as models to study the influence of different therapeutic agents in reverting the epigenetic Parkinson's disease state (Valente et al., 2012) .
Currently, there is a broad spectrum of different biological assays available to quantify cell proliferation and/or cytotoxicity (Bopp and Lettieri, 2008) . The most common methods used include assays based on measuring cell membrane integrity by lactate dehydrogenase leakage or by inclusion/exclusion of dyes (crystal violet, trypan blue, and neutral red), and methods of cell counting or quantification of protein mass, which include quantification of protein concentration or the sulforhodamine B (SRB) assay, as well as tests based on the metabolic activity of viable cells by reduction of tetrazolium salts [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-phenylamino-carbonyl)2 H-tetrazolium hydroxide (XTI'), 5-(3-carboxymethoxyphenyl)-2-(4,5-dimethylthiazoly)-3-(4-sulfophenyl)tetrazolium, inner salt (MTS), and 4-[3-4-iodophenyl]-2-(4-nitrophenyl)-2 H-5-tetrazolio)-1,3-benzene disulfonate (WST-1)] or resazurin (Voytik-Harbin et al., 1998; Niles et al., 2008) . However, these assays measure only one cellular parameter, making them restrictive and easily prone to artifacts. For this reason, the selection of proper cytotoxic assays is generally a highly complex process, which takes into account different factors such as the nature and duration of the assay, the detection mechanism required, and the structure of the chemical compound to be tested. Moreover, discrepancies between methods used by various research groups often complicate comparison of results between independent research studies. There is an increasing need for the development of simple, rapid, reliable, and highly reproducible cell viability assays, which may be standardized and routinely used in a great number of in vitro cellular systems. The protocol described here shows the development of a more rapid and reliable cell viability method to be used in preliminary screening of chemical compounds. This procedure measures metabolic activity and cell mass in tandem, for the same cell sample, using a dual resazurin/SRB assay, thereby eliminating the variation associated with different assays and changes in external conditions, e.g., CO 2 levels, temperature, and medium composition, which can occur if resazurin and SRB assays are not performed in the same sample (e.g., multi-well plate). The procedure presented here is divided in three parts-cell culture conditions (Basic Protocol 1), determination of metabolic activity by resazurin reduction assay (Basic Protocol 2), and quantification of cell mass using the SRB assay (Basic Protocol 3).
100-cm
2 cell culture dishes Cell incubator, at 37°C with 5% CO 2 atmosphere Inverted microscope 15-ml disposable conical polypropylene centrifuge tubes (e.g., Corning Falcon) Additional reagents and equipment for cell culture, including counting cells and determining number of viable cells by trypan blue exclusion (APPENDIX 3B; Phelan, 2007) NOTE: The PBS, trypsin-EDTA, and growth medium (complete DMEM) should be preheated to 37°C just before use.
NOTE:
Repeat each experiment at least three times using cells from independent cultures.
1. Grow cells on 100-cm 2 cell culture dishes in growth medium in a 37°C, 5% CO 2 incubator until density reaches 70% to 80% confluence.
APPENDIX 3B (Phelan, 2007) includes protocols for cell culture.
2. Remove the medium and wash the cell monolayer once with PBS.
3. Add 5 ml of 0.05% trypsin-EDTA and keep the plate in the incubator for 5 to 7 min at 37°C in order to harvest adherent cells. Add 5 ml of complete DMEM medium (with FBS) to inhibit trypsin.
4. Transfer the cell suspension to a 15-ml polypropylene conical centrifuge tube and centrifuge 5 min at 500 × g, room temperature.
5. Discard the supernatant and resuspend the pellet in 1 or 2 ml of growth medium.
6. Mix 10 μl of cells suspension with 10 μl of 0.4% trypan blue and count viable cells in a hemacytometer.
More detail on the trypan blue exclusion test for cell viability can be found in APPENDIX 3B (Phelan, 2007) . Use each row to plate a different cell density (plate eight wells for each density); just add growth medium to the wells in the first row and use this row as an internal control.
8. Leave cells growing for 24, 48, 72, 96, 120, 144, 168, and 192 hr, using a column for each time point (see Fig. 2 .24.1 for plate map). At the end of each time point, proceed to Basic Protocol 2, where the resazurin solution will be added to the column corresponding to the respective time point of incubation. After fluorescence measurements, return the plate to the incubator until the next time point is measured.
9. Change the growth medium every 2 days until reaching 192 hr.
BASIC PROTOCOL 2

RESAZURIN ASSAY FOR CELL VIABILITY ASSESSMENT
The following protocol describes how to optimize the resazurin assay with different cell densities of BJ skin fibroblasts and different incubation times with resazurin, measuring the metabolic activity through the fluorescence intensity in a 48-well microplate reader format. Other cell lines may also be used, but the different cell densities and times of incubation with resazurin must be optimized.
Materials
Cells seeded in 48-well plates (see Basic Protocol 1) Resazurin solution (see recipe) Phosphate-buffered saline (PBS; see recipe) Growth medium (see recipe)
Microplate reader Computer running MS Excel and GraphPad Prism or SPSS (IBM)
1. For each cell growth time point (24, 48, 72, 96, 120, 144, 168, and 192 hr; see Basic Protocol 1, step 8), take the plate out of the cell incubator.
2. Remove the medium from each well in the column corresponding to the present time point and wash with PBS.
3. After removing the PBS wash, add 500 μl of resazurin solution (freshly prepared each day from a 1:1000 dilution in growth medium from a stock solution) per well to the wells in the column corresponding to the specific treatment/culture time to be studied (see Fig. 2 .24.1 for plate map).
Resazurin solution should be prepared under aseptic conditions and protected from light with aluminum foil.
The plate should also be covered with aluminum foil; change the foil daily to avoid the possibility of contamination.
4. Place the plate, covered with aluminum foil, in the incubator for 30 min at 37°C with a 5% CO 2 atmosphere.
5. Measure resorufin fluorescence (using excitation wavelength of 540 nm and emission of 590 nm) using a microplate reader.
6. Repeat the measurements at 60, 240, and 360 min.
7. At the last incubation time point (360 min), carefully remove the resazurin solution and medium.
8. Wash the corresponding column of adherent cells with 200 μl of prewarmed (37°C) PBS, carefully remove the PBS, and place the plate back in the incubator.
Data analysis
9. Export data from the microplate reader in Excel format.
10. Represent the data with relative fluorescence units on the y axis and time of incubation with resazurin or time of cell culture on the x axis to determine the corresponding time-point for maximum viability, using software such as GraphPad Prism or SPSS.
BASIC PROTOCOL 3
SULFORHODAMINE B COLORIMETRIC ASSAY
The protocol outlines the procedure for the SRB assay, which is performed on the same set of skin BJ fibroblasts used to perform the resazurin assay. The SRB method will now measure cell mass ("protein") through determination of the absorbance of each sample in a 96-well microplate reader format. When using the SRB assay, cell protein is indirectly equivalent to total cell mass, which in turn correlates with cell number (Papazisis et al., 1997) . Other cell lines may also be used, but the range of cell densities must be optimized based on the specificity of each cell type.
Materials
Cells seeded in 48-well plates, after performing resazurin assay for all time points (see Basic Protocol 2) Phosphate-buffered saline ( 2. Add 500 μl of 1% acetic acid in methanol to each well on the whole plate.
3. Cover the plate with aluminum foil and incubate at −20°C at least 3 hr or overnight, in order to promote cell fixation.
4. Discard the 1% acetic acid solution and dry the plate in an incubator at 37°C for ß1 hr. The 48-well plate should be placed in the incubator with the lid open.
5. Add 250 μl of SRB solution in each well and incubate for 1 hr at 37°C.
6. Discard the SRB solution and wash wells with 1% acetic acid prepared in MilliQpurified water.
7. Dry the plate in the incubator at 37°C for 1 hr or overnight.
8. Add 250 μl of 10 mM Tris-NaOH, pH 10, and stir the plate for 30 min on an orbital plate shaker at room temperature.
9. Transfer 100 μl from each well to a 96-well plate and read the absorbance at 510 nm and background measurement at 620 nm, at room temperature.
Data analysis
10. Export data from microplate reader in Excel format.
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11. Represent the data with absorbance on the y axis and time of cell culture on the x axis, using software such as GraphPad Prism or SPSS. 
REAGENTS AND SOLUTIONS
Acetic acid solution in methanol, 1% (v/v)
Add 5 ml acetic acid to 495 ml methanol, homogenize the solution, and store up to 1 year at −20°C.
Acetic acid solution in MilliQ-purified water, 1% (v/v)
Mix 10 ml acetic acid with 990 ml MilliQ-purified water, and store at room temperature.
Growth medium
Dulbecco's modified Eagle medium (DMEM; Sigma, cat. no. D5030) supplemented with: 25 mM glucose 4 mM glutamine 1 mM sodium pyruvate 21 mM sodium bicarbonate 10% fetal bovine serum (FBS; Invitrogen, cat. no. 16000-044) 1× penicillin-streptomycin [100 U/ml penicillin/100 μg/ml streptomycin; add from 100× (10,000 U/ml penicillin/10,000 μg/ml streptomycin; Invitrogen, cat. no. 15140-122)] Dissolve 8.3 g of DMEM powder, 4.5 g of glucose, 0.584 g of glutamine, 0.11 g of sodium pyruvate, and 1.8 g sodium bicarbonate in 800 ml MilliQ-purified water. Adjust to pH 7.2 to 7.4 using HCl or NaOH and bring the solution to 890 ml with MilliQ-purified water. Supplement the solution with 100 ml FBS and 10 ml of 100× penicillin-streptomycin, and filter with a 0.2-μm filter under aseptic conditions. Keep sterile and store up to 1 month at 4°C.
Phosphate-buffered saline (PBS)
Dissolve 8 g NaCl, 0.2 g KCl, 0.61 g Na 2 HPO 4 , and 0.2 g KH 2 PO 4 in 900 ml MilliQ-purified water. Adjust pH to 7.4 using HCl or NaOH and bring the solution to a final volume of 1 liter with MilliQ-purified water. Autoclave the solution. Store this solution up to 1 year at room temperature and always shake before use.
Resazurin stock solution, 1 mg/ml Dissolve 1 mg of resazurin in 1 ml in sterile PBS (see recipe). Filter the solution using a 0.2-μm filter, protect the solution from light with aluminum foil, and keep frozen up to 1 month at −20°C. On the day of the assay, defrost the resazurin solution in a 37°C water bath, and further dilute the 1:1000 solution in growth medium (see recipe) under aseptic conditions. SRB solution, 0.05% (w/v) Dissolve 0.25 g of sulforhodamine B (SRB; Sigma, cat no. S9012) in 500 ml of of 1% (v/v) acetic acid in MilliQ-purified water, and keep protected from light with aluminum foil. Store this solution up to 1 year at 4°C.
Tris-NaOH, 10 mM, pH 10 Dissolve 0.64 g of Tris base in 400 ml of MilliQ-purified water. Adjust pH to 10.5 with 1 M NaOH and bring the solution to a final volume of 500 ml with MilliQ-purified water. Store this solution up to 1 year at room temperature.
COMMENTARY Background Information
Decreasing the cost of developing new compounds and improving their time to market are two great challenges for pharmaceutical industry (Adams and Brantner, 2006; Taylor, 2015) . Pre-clinical tests that can predict drug behavior in humans before reaching clinical assays are the standard approach in drug-development pipelines (Brodniewicz and Grynkiewicz, 2010) . Cell viability assays that simultaneously measure the cell mass and metabolic activity in the same sample of cells may be considered important tools to predict human toxicity and to detect toxic thresholds of different types of chemicals.
Here we describe a cell viability method that can measure cell mass and metabolic activity using a tandem resazurin/SRB assay in skin BJ fibroblasts.
The resazurin reduction test (also known as Alamar Blue assay) was developed in the 1950s to assess bacterial or yeast contamination in biological fluids and milk (Erb and Ehlers, 1950) . It still has current widespread use in measuring the metabolic activity of mammalian cells (Fields and Lancaster, 1993) . In this assay, viable cells with active metabolism reduce resazurin (nonfluorescent dye, blue) to resorufin (pink fluorescent dye; see Fig. 2 .24.2), with fluorescence output being proportional to the number of metabolically active and viable cells (O'Brien et al., 2000; Abdoli et al., 2015) . The principal advantages of this assay are simplicity, versatility, reproducibility, sensitivity, and low cost (Voytik-Harbin et al., 1998) , as well as the fact that it does not involve cell lysis and can be performed with other tests or kinetic measurements on the same set of cells (Zumpe et al., 2010) . The main disadvantages of this method are possible fluorescent interference of 2.24.7 tested compounds, and intrinsic toxicity of resazurin for particular cell types (Riss et al., 2004) , although this can be easily assessed by performing proper controls with alternative viability assays. The sulforhodamine B assay is another technique currently used for measuring cell mass, which was established by Skehan et al. (1990) and subsequently adopted for routine use in the National Cancer Institute in vitro antitumor screen (Kerkvliet, 1990; Abdoli et al., 2015) . This assay infers cell growth by direct quantification of total protein mass, not relying on the direct determination of the metabolic function or activity of living cells (Papazisis et al., 1997) , thus eliminating the influence of varying biological parameters such as increased metabolic rate or variations in mitochondrial activity. This assay is based on binding of the SRB dye to basic amino acids in cellular proteins, with a colorimetric evaluation providing an estimate of total cellular protein, which is related to cell number (Papazisis et al., 1997) . The advantages of the SRB assay include the lower cost, good linearity, higher sensitivity, and stable endpoint (Papazisis et al., 1997) . Therefore, the tandem combination of these two assays would allow evaluation of metabolic activity of a known cell population, which is calculated from its mass, resulting in a more confident prediction of the human toxicity and detection of toxic thresholds for the tested compounds.
Critical Parameters and Troubleshooting
Critical Parameters and Troubleshooting are summarized in Table 2 .24.1.
Anticipated Results
The results of the study shown here provide insights for optimization of a dual resazurin/sulforhodamine B assay, which can easily be used in different cell lines. This is an innovative, simple, highly reproducible, and informative cell viability assay that measures cell mass and metabolic activity in the same cell sample, eliminating the variation associated with cell seeding and also minimizing time and costs associated with conducting separate assays for individual cell samples. In the optimization process for the dual resazurin/sulforhodamine B assay, it is imperative to first determine the optimal incubation time with resazurin that is required to measure cellular metabolic activity, since this factor largely influences the sensitivity of this assay. Selection of the incubation period should take into account the smallest possible time of incubation required to reflect a practical conversion of all resazurin, and, whenever possible, the time that most accurately reflects the differences in the cell densities used. One example is shown in Figure 2 .24.3, where skin BJ fibroblasts seeded at different densities (0.25, 0.5, 1, 2, and 4 × 10 4 cells /cm 2 ) and different culture times (24, 48, 72, 96, 120, 144, 168, and 192 hr) present an optimal incubation time with resazurin of 6 hr. In this case, it is clear that 6 hr is the minimal time of incubation that reflects a practical conversion of all resazurin. In fact, increasing the time of incubation with resazurin up to 8 hr does not improve the resolution of the fluorescence signal in detecting different cell densities (Figs. 2.24.3 and 2.24.4) .
It should be noted, however, that the optimal time of incubation with resazurin changes mainly with the metabolic activity of cells and cell density used. It is thus expected that cells with higher metabolic activity require a shorter time of incubation with resazurin, while cells with lower metabolic activity may require a longer time of incubation with resazurin. Accordingly, some examples of different cell lines used in our laboratory with different incubation times with resazurin are shown in Table 2 .24.2, which may be a helpful tool to predict the range of incubation times for a given cell line.
After choosing the optimal incubation time with resazurin, one should proceed to the analysis of metabolic activity and cell mass separately along the time of cell culture (for the optimal time of incubation with resazurin). Figures 2.24.5 and 2.24.6 demonstrate the variation of metabolic activity and cell mass of skin BJ fibroblasts along different culture times, incubating with resazurin for 6 hr.
The final step is to establish a correlation between metabolic activity and cell mass, since this parameter provides a reliable determination of cell viability. As observed in Figure 2 .24.7, this allows accurate determination of whether metabolic activity is directly proportional to cell density. However, it should be noted that analysis of this parameter can confirm that the resultant fluorescent signal is an accurate reflection of cellular metabolic activity devoid of any interference from factors such as resazurin toxicity or fluorescent quenching. 
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Figure 2.24.5 Metabolic activity of skin BJ fibroblasts along different culture times, measured by the resazurin assay. Skin BJ fibroblasts seeded at different densities (0.25, 0.5, 1, 2, and 4 × 10 4 cells /cm 2 ) in DMEM medium were kept in culture during 24, 48, 72, 96, 120, 144, 168, and 192 hr, and then incubated with resazurin for 6 hr. Metabolic activity was determined by resorufin fluorescence measurement using 450 nm excitation/490 nm emission, and expressed in relative fluorescence units. The arrows correspond to time points when replacement of cell culture medium occurred. The values are expressed as mean ± SEM (standard error of the mean) of four independent experiments (when the error bars are not visible, SEM is hidden by the size of the symbols).
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Figure 2.24.6 BJ fibroblasts mass along different times in culture, as measured by the sulforhodamine B assay. Skin BJ fibroblasts seeded at different densities (0.25, 0.5, 1, 2, and 4 × 10 4 cells /cm 2 ) in DMEM medium were kept in culture during 24, 48, 72, 96, 120, 144, 168, and 192 hr. Cell mass was determined by the measurement of optical density at 510 nm wavelength against background measured at 620 nm. Each point represents the mean ± SEM (standard error of the mean) of four independent experiments (when the error bars are not visible, SEM is hidden by the size of the symbols). Correlation between cell mass and metabolic activity of skin BJ fibroblasts along different culture times. Skin BJ fibroblasts cells seeded at 4 × 10 4 cells /cm 2 in DMEM medium were kept in culture during 24, 48, 72, 96, 120, 144, 168 and 192 hr. Cell mass was determined by measuring optical density at 510 nm against 620 nm background, and metabolic activity determined by resorufin fluorescence measurement at 6 hr using 450 nm excitation/490 nm emission wavelength, and expressed in relative fluorescence units. The values are represented as mean ± SEM (standard error of the mean) of four independent experiments (when the error bars are not visible, SEM is hidden by the size of the symbols). The funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of this document.
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